Nutra Pharma Corp. Announces Publication Of Positive Results Of ReceptoPharm Pain Study

BOCA RATON, Fla.--(BUSINESS WIRE)--Aug. 21, 2006--Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has announced that its subsidiary, ReceptoPharm, has published positive results from its recent study on the use of cobratoxin for the relief of pain. ReceptoPharm is currently studying the effectiveness of Cobra Venom and Cobratoxin as treatments for Multiple Sclerosis, HIV, Adrenomyeloneuropathy (AMN), and Rabies.